FDA Rejects Organon’s Livial For Menopause
This article was originally published in The Pink Sheet Daily
Executive Summary
Akzo Nobel healthcare group Organon plans to continue ongoing trials of tibolone for other indications.
You may also be interested in...
Organon Ends Livial Program In The U.S.
Oraganon will drop all efforts to market its hormone therapy Livial (tibolone) in the United States following a June 1 "not approvable" letter. The company was seeking an indication for treatment of menopausal symptoms
Organon Ends Livial Program In The U.S.
Oraganon will drop all efforts to market its hormone therapy Livial (tibolone) in the United States following a June 1 "not approvable" letter. The company was seeking an indication for treatment of menopausal symptoms
Organon Considering Partnership For Hormone Therapy Livial In U.S.
Organon is considering finding a partner to support the introduction of its hormone therapy Livial (tibolone) in the U.S